Statement-II

Applications for patents at indian patent office (IPO) in the years

2003-04 *to* 2004-05

Applicants	2003-04	2004-05
Indians	3218	3630
Foreigners Resident Abroad	1678	3165

SOURCE: Annual Reports of the Controller General of Patens, Designs and Trade Marks.

NOTE: Foreigners Resident Abroad include broadly the residents of Common wealth Countries, American, European, African and Asian countries.

Applications for patents filed through PCT in the years

2003-04 *to* 2004-05

PCT Applicants	2003-04	2004-05
Indians*	764	723
Foreigners Resident Abroad	7717	10671

* Data refers to calendar year.

SOURCE: Annual Reports of the Controller General of Patents, Designs and Trade Marks. World Intellectual Property Organisation (WIPO), Geneva *www.wipo.int*

NOTE: Foreigners Resident Abroad include broadly the residents of Common wealth Countries, American, European, African and Asian countries.

Indian applicants include patents filed by Indians through PCT designating foreign countries.

Foreigners Resident Abroad include patents filed through PCT designating India.

Approval of genetically-engineered products

1299. SHRI NANDI YELLAIAH: Will the Minister of SCIENCE AND TECHNOLOGY be pleased to state:

(a) whether single window agency for approval of genetically-engineered products had been introduced;

(b) if so, the details thereof;

(c) if not, whether Government would assure of introducing the same at the earliest to drastically cut-short the time involved and various bureaucratic, red-tapism hurdles, in approving the products; and

(d) if not, the reasons therefor?

THE MINISTER OF SCIENCE AND TECHNOLOGY (SHRI KAPIL SIBAL): (a) and (b) No Sir, there is no single window clearance mechanism available in the Government for approval of genetically engineered products.

(c) and (d) There are standard procedures as per the prevailing Rules-1989 of Environment (Protection) Act, 1986 to cut short the time involved in approving the genetically-engineered products.

Indian Sub-group on Clinical Research and Transfer of Bio-Materials

1300. SHRIMATI N.P. DURGA: Will the Minister of SCIENCE AND TECHNOLOGY be pleased to state:

(a) whether Indian Sub-group on Clinical Research and Transfer of Bio-materials under Indo-US Joint Industry Working Group on bio-technology recommended for a new drug authority body on the lines of TRAI and IRDA;

(b) what are the other recommendations made to bring about regulatory and fiscal changes to remove procedural and other impediment in bio-technology sector;

(c) whether it is also a fact that the bio-technology industry is also demanding to treat clinical research expenditure as R&D expenditure; and

(d) if so, the reasons therefor and what benefit would the industry get if it is treated as R&D expenditure?

THE MINISTER OF SCIENCE AND TECHNOLOGY (SHRI KAPIL SIBAL): (a) Yes, Sir.

(b) Other recommendations are—

A. Regulatory

1) A single window clearance mechanism with standard operating procedures (SOPs) for import and export of biologicals; clinical trial and pharmacogenomic samples and export of Special Chemicals, Organisms, Materials, Equipment & Technologies (SCOMET) items.

2) Development of policy guidelines for clinical trials.